

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG  
Form 6-K  
January 18, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated January 18, 2002

Novartis AG  
(Name of Registrant)

Lichtstrasse 35  
4056 Basel  
Switzerland

-----  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

--- ---

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

--- ---

Enclosure:

1. Invitation for the Full Year Results 2001 Presentation.

[NOVARTIS LOGO]

Investor Relations

Novartis International AG  
CH-4002 Basel  
Switzerland  
Karen J. Huebscher, Ph.D.  
Tel + 41 61 324 8433  
Nafida Bendali  
Tel + 41 61 324 3514  
Sabine Moravi, MBA  
Tel +41 61 324 8989

Edgar Filing: NOVARTIS AG - Form 6-K

Silke Zentner  
Tel +41 61 324 8612  
Francisco Bouzas  
Tel +41 61 324 2462  
Fax +41 61 324 8444  
Internet Address:  
<http://www.novartis.com>

-----  
- Full Year Results 2001 -  
-----

The Executive Committee of Novartis has great pleasure in inviting you to the presentation of the 2001 results and business developments. The meeting will take place on

Thursday, February 7, 2002

At 1.30 PM for a 2.00 PM prompt start at the

Kongresszentrum in Basel

Messeplatz 21

Basel, Switzerland  
-----

Following the presentation, refreshments will be served.

We hope that you will be able to attend. Please find attached a reply form for your convenience.

-----  
- Reply form -  
-----

- [ ] I will attend the Basel Presentation on February 7, 2002  
[ ] I will follow the presentation on the Internet

Edgar Filing: NOVARTIS AG - Form 6-K

First name \_\_\_\_\_  
Last name \_\_\_\_\_  
Company \_\_\_\_\_  
Address \_\_\_\_\_  
\_\_\_\_\_  
Fax \_\_\_\_\_  
E-mail \_\_\_\_\_

Please send your response by mail or fax no later than February 1, 2002 to:

Novartis International AG  
Raquel Rodriguez  
Lichtstrasse 35  
CH-4002 Basel  
Fax # +41 61 324 8444  
E-mail: raquel.rodriguez@group.novartis.com

-----  
- Full Year Results 2001 webcast and dial-in numbers -  
-----

If you wish to follow our Full Year Results presentation as a webcast on the Internet, please use the following link:  
<http://www.novartis.com/investors/index.shtml>  
-----

If you prefer to dial into the conference through a telephone line we also offer the following dial-in numbers. The presentations will be available on the website and least 1 hour prior to the start of the event.

Date: Thursday, February 7, 2002  
Time: Advisable: dial-in 15 minutes before  
2.00 p.m. Switzerland  
1.00 p.m. UK  
8.00 a.m. New York  
Phone numbers: +41 (0) 848 22 41 11 Europe  
+1 800 860 24 42 USA

Playback for 72 hrs after the call commencing

Edgar Filing: NOVARTIS AG - Form 6-K

Date: Thursday, February 7, 2002  
Time: 6.00 p.m. (Switzerland)  
5.00 p.m. (UK)  
12.00 p.m. (New York)  
Phone numbers: +41 (0) 848 72 25 00 Europe  
+1 877 344 75 29 USA  
Code: 539#

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novartis AG

Date: January 18, 2002

By: /s/ RAYMUND BREU

-----  
Name: Raymund Breu  
Title: Chief Financial Officer